SavedAdd your journal

Journals / Akdeniz Tıp Dergisi / 2021 / Cilt: 7 - Sayı: 1

Poor Outcomes of Solid Organ Cancers After Renal Transplantation: A Single-Center Experience

Renal Transplantasyon Sonrası Gelişen Solid Organ Kanserlerinin Kötü Sonlanımları: Tek Merkez Deneyimi

Derya KIVRAK SALİM
Hasan Şenol COŞKUN
Sema SEZGİN GÖKSU
Hüseyin KOÇAK
Pages
36–44
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Objective: This study aimed to describe survival and its influencing factors in post-renal transplant patients with solid organ cancers.Material and Methods: In this retrospective, observational study overall survival was the primary endpoint.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to describe survival and its influencing factors in post-renal transplant patients with solid organ cancers.Material and Methods: In this retrospective, observational study overall survival was the primary endpoint.
📊
Key Findings & Data:Results: In total, 39 patients were included.
💡
Conclusion & Impact:Primary tumor resection predicted better OS p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Solid kanserler · Böbrek nakli alıcısı · Sağ kalım

Abstract

Objective: This study aimed to describe survival and its influencing factors in post-renal transplant patients with solid organ cancers.Material and Methods: In this retrospective, observational study overall survival was the primary endpoint. Results: In total, 39 patients were included. The median malignancy development time after transplantation was 49 months. The median overall survival was 24 months and the median progression-free survival was 16 months. Primary tumor resection predicted better OS p

Özet

Amaç: Bu çalışmada, böbrek nakil sonrası solid organ kanseri gelişen hastalarda sağ kalımı etkileyen faktörlerin tanımlanması amaçlandı.Gereç ve Yöntemler: Bu retrospektif gözlemsel çalışmada birincil sonlanım noktası genel sağ kalım idi. Bulgular: Toplamada 39 hasta çalışmaya dahil edildi. Ortanca maligniteye kadar geçen süre 49 ay idi. Ortanca genel sağ kalım 24 aydı ve ortanca progresyonsuz sağ kalım 16 aydı. Primer tümör rezeksiyonu daha iyi OS p

🔖

Cite This Article

SALİM, D. K., COŞKUN, H. Ş., GÖKSU, S. S., KOÇAK, H. (2022). Poor Outcomes of Solid Organ Cancers After Renal Transplantation: A Single-Center Experience. Akdeniz Tıp Dergisi, Cilt: 7 - Sayı: 1, 36–44. https://ajindex.com/articles/434244

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Garcia GG, Harden P, Chapman J. The global role of kidney transplantation. Curr Opin Nephrol Hypertens 2012; 21:229-34.
  2. Torbenson MS, Wang J, Nichols L, Jain AB, Fung JJ, Nalesnik MA. Occult nonhematopoietic malignancies present at autopsy in solid organ transplant patients who died within 100 days. Transplantation 2001; 71:64. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet 1995;346(8972):403-6.
  3. Pecqueuxa JC, Schwarzb A, Dieckmanna KP, Offermannb G. Cancer incidence in patients on chronic dialysis and in renal transplant recipients. Urol Int 1990; 45:290-2.
  4. Stallone G, Infante B, Grandaliano G. Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J 2015; 8:637-44.
  5. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4:905-13. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16:1545-9.
  6. Jain A, DiMartini A, Kashyap R, Youk A, Rohal S, Fung J. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 2000; 70:1335-42.
  7. Gallo P, Agozzino L, Angelini A, Arbustini E, Bartoloni G, Bernucci P, Bonacina E, Bosman C, Catani G, di Gioia C, Giordana C, Leone O, Motta T, Pucci A, Rocco M. Causes of late failure after heart transplantation: A ten-year survey. J Heart Lung Transplant 1997; 16:1113- 21. Sheil AGR, Disney APS, Mathew TH, Amiss, N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25:1383-4 Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1994; 99-109.
  8. Dantal J, Pohanka E. Malignancies in renal transplantation:an unmet medical need. Nephrol Dial Transplant 2007; (Suppl 1):4-10.
  9. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, Wolfe RA, Jones E, Disney AP, Briggs D, McCredie M, Boyle P. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 1999; 354:93-9.
  10. Coghill AE, Johnson LG, Berg D, Resler AJ, Leca N, Madeleine MM. Immunosuppressive medications and squamous cell skin carcinoma: Nested case-control study within the Skin Cancer after Organ Transplant (SCOT) Cohort. Am J Transplant 2016; 16:565-73.
  11. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of